Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo by Kirill Kukhmar/TASS via Getty Images

Emulate, a Boston-based developer of "organs-on-chips," raised $36 million in new venture capital funding led by Peter Thiel's Founders Fund.

Why it's a big deal: Because this technology could reduce the large number of animals used each year in pharmaceutical lab testing, without sacrificing efficacy.

  • Emulate currently has partnerships with such drug-makers as AstraZeneca, Merck, Roche, Takeda and Johnson & Johnson.
  • Other investors in the "Series C" round include ALS Investment Fund, SciFi VC and Glass Wall Syndicate.

More detail from Xconomy's Frank Vinluan:

"The translucent Emulate chips, roughly the size of a AA battery, have tiny channels lined with human cells and tissue. These chips are engineered to recreate the physiology and mechanical forces encountered by the cells of an organ, such as the flow of blood or air. Emulate has developed organ chips for the liver, intestine, lung, and the brain. Those chips are part of a broader system that includes instruments for conducting experiments and software to analyze data and model different diseases."

Go deeper

2 hours ago - Health

Beware a Thanksgiving mirage

Illustration: Sarah Grillo/Axios

Don't be surprised if COVID metrics plunge over the next few days, only to spike next week.

Why it matters: The COVID Tracking Project warns of a "double-weekend pattern" on Thanksgiving — where the usual weekend backlog of data is tacked on to a holiday.

Trump pardons Michael Flynn

President Trump with Michael Flynn in 2016. Photo: David Hume Kennerly/Getty Images

President Trump on Wednesday pardoned his former national security adviser Michael Flynn, who pleaded guilty in the Mueller investigation to lying to FBI agents about his conversations with a former Russian ambassador.

Why it matters: It is the first of multiple pardons expected in the coming weeks, as Axios scooped Tuesday night.